US 12,441,789 B2
DLL3-targeting antibodies and uses thereof
John T. Poirier, New York, NY (US); Charles Rudin, New York, NY (US); Jason Lewis, New York, NY (US); Abdul Khan, New York, NY (US); David Andrew, New York, NY (US); Xinlei Chen, New York, NY (US); and Ivo Lorenz, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US); and Tri-Institutional Therapeutics Discovery Institute, New York, NY (US)
Appl. No. 17/622,404
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US); and TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, NY (US)
PCT Filed Jul. 8, 2020, PCT No. PCT/US2020/041282
§ 371(c)(1), (2) Date Dec. 23, 2021,
PCT Pub. No. WO2021/007371, PCT Pub. Date Jan. 14, 2021.
Claims priority of provisional application 62/872,915, filed on Jul. 11, 2019.
Prior Publication US 2022/0348648 A1, Nov. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01)] 17 Claims
 
1. An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein
(a) the VH comprises a VH-CDR1 sequence, a VH-CDR2 sequence, and a VH-CDR3 sequence selected from the group consisting of
(i) SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively;
(ii) SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, respectively;
(iii) SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively; and
(iv) SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, respectively;
and
(b) the VL comprises a VL-CDR1 sequence, a VL-CDR2 sequence, and a VL-CDR3 sequence selected from the group consisting of
(i) SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively;
(ii) SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, respectively;
(iii) SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30, respectively; and
(iv) SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40, respectively.